Welcome to our dedicated page for Marex Group SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Marex Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Marex Group's regulatory disclosures and financial reporting.
Marex Group plc filed a Form 13F reporting its institutional equity holdings. The filing lists 901 Form 13F information table entries with a total value of $11,529,406,132 and identifies 4 other included managers. The report was signed by Jae Cho, Director on 08-18-2025.
Marex Group plc submitted a Form 6-K to provide investors with its interim 2025 financial information. The company furnished a press release titled “Marex Group plc Interim 2025 Results,” issued on 13 August 2025, along with Condensed Consolidated Financial Statements for Marex Group for the six months ended June 30, 2025. These materials are included as Exhibits 99.1 and 99.2, giving readers access to the company’s mid‑year performance details and supporting financial statements.
Marex Group has filed a Form 144 notice for the proposed sale of 210,000 shares of common stock through J.P. Morgan Securities, with an aggregate market value of $8,219,400. The sale is scheduled for June 23, 2025, on the Nasdaq exchange.
The securities to be sold were acquired through multiple compensation grants:
- May 2024: 29,243 shares total
- March 2025: 105,122 shares total
- May 2025: 75,635 shares
The total shares outstanding are 71,231,706. The proposed sale represents approximately 0.29% of outstanding shares. No securities were reported sold by the filer during the past three months. This Form 144 filing indicates insider's intention to sell while affirming no knowledge of undisclosed material adverse information about the company.